A Care Team’s Access to
Actionable Information at Your Fingertips; Anywhere, Anytime
With thousands of cancer treatment studies published every day and novel therapeutics and treatment regimens continually entering the pipeline, it’s impossible for practicing clinicians on the front lines of cancer care to keep up.
- How do you find the latest information relevant to each patient’s diagnosis, treatment options, and symptomatology?
- How do you monitor each patient’s daily health and symptom status and synthesize that data in the context of exploding literature and deep specialty and subspecialty expertise? Without an easy way to do this, how can you optimally manage the treatment course, particularly when the patient is at high risk of developing treatment-related adverse effects?
- What adjustments in the patient’s treatment are likely to be most effective while mitigating the risks of dangerous adverse events?
- And how do you detect the emergence of such adverse events so you can intervene early to minimize potentials of severe or life-threatening toxicities?
Apricity Health Offers a Digital Solution
ApricityOncology is a powerful digital platform that connects you to your patients, helps you continually monitor their status for early detection and timely intervention.
You can use daily patient-reported outcome data, in combination with the most relevant and up-to-date expert knowledge, to adjust and optimize your patient’s care.
What’s more, you can call up the patient-reported data at your fingertips in an instant, along with expert augmented guideline-based advisory — on a smartphone, a tablet, or a computer.
Designed for Oncology Teams,
by Oncology Experts
ApricityOncology does the work of synthesizing complex data to help you and your team devise optimal treatment plans for your patients. The platform is the creation of renowned clinicians and scientists who are passionate about improving care for all patients.
Apricity Health Founders
Lynda Chin, MD, President, CEO and Co-Founder, is an elected member of the National Academy of Medicine, Dr. Chin is a renowned cancer genomic scientist and a leader in the application of technologies, AI/ML and big data in medicine.
Keith Flaherty, MD, Co-Founder, is Director of Clinical Research at the Massachusetts General Hospital Cancer Center, and Professor of Medicine at Harvard Medical School. As described in the more than 300 peer-reviewed primary research reports he has authored or co-authored, Dr. Flaherty and colleagues made several seminal observations that have defined the treatment of melanoma.
Padmanee Sharma, MD/PhD, Co-Founder, is a nationally and internationally renowned physician scientist whose research work is focused on investigating mechanisms and pathways within the immune system that facilitate tumor rejection, with subsequent clinical benefit, or elicit resistance to immune checkpoint therapy.
James Allison, PhD, is founding advisor and Chair of the Scientific Advisory Board. He has spent a distinguished career studying the regulation of T cell responses and developing strategies for cancer immunotherapy. He earned the 2018 Nobel Prize in Physiology or Medicine, which he shared with Dr. Tasuku Honjo, “for their discovery of cancer therapy by inhibition of negative immune Regulation.”
Apricity Health Advisors and Collaborators
Dr. Bhardwaj is Professor of Medicine and Urology, Director of Immunotherapy, Medical Director of the Vaccine and Cell Therapy Laboratory, and Co-Director of the Cancer Immunology Program at The Tisch Cancer Institute. Former chair of the Cancer Immunology Steering Committee of the American Association for Cancer Research, she is editor for Cancer Immunology Research and Frontiers in Immunology, holds the Ward Coleman Chair in Cancer Research, and has made seminal contributions to human dendritic cell biology.
Dr. Hodi is the Director of the Melanoma Center and the Center for Immuno-Oncology at Dana-Farber/Brigham and Women’s Cancer Center and Professor of Medicine at Harvard Medical School. He received his MD degree from Cornell University Medical College in 1992. Dr. Hodi completed his postdoctoral training in Internal Medicine at the Hospital of the University of Pennsylvania and Medical Oncology training at Dana-Farber Cancer Institute where he joined the faculty in 1995.
Dr. Lacouture is an Associate Professor and the director of the Oncodermatology Program in the Dermatology Service at Memorial Sloan Kettering Cancer Center in New York City. He did his postdoctoral work at Brigham and Women’s Hospital in Boston, MA, an internship in General Surgery at Cleveland Clinic and residency in dermatology at The University of Chicago, IL.
Dr. Mackall is an Endowed Professor of Pediatrics and Medicine at Stanford University. She is Founding Director of the Stanford Center for Cancer Cell Therapy, Associate Director of Stanford Cancer Institute, and Director of the Parker Institute for Cancer Immunotherapy at Stanford.
Dr. Newcomer served as Chief Medical Director at UnitedHealth Group, Medical Director for Cigna Healthcare, founding executive of Vivius, and former Chairman of Park Nicollet Health Services. He completed a Masters of Health Administration from the University of Wisconsin, his residency at the University of Nebraska Medical Center, and a medical oncology fellowship at the Yale University School of Medicine. He earned a MD from the University of Nebraska College of Medicine, and a BA from Nebraska Wesleyan University.
Dr. Ribas is Professor of Medicine, Professor of Surgery, and Professor of Molecular and Medical Pharmacology at the University of California Los Angeles (UCLA), Director of the Tumor Immunology Program at the Jonsson Comprehensive Cancer Center (JCCC), Director of the Parker Institute for Cancer Immunotherapy (PICI) Center at UCLA.
Dr. Rizvi is an internationally recognized leader in the treatment of lung cancer and immunotherapy drug development. He currently serves as the Price Family Professor of Medicine and Director of Thoracic Oncology as well as Co-Director of Cancer Immunotherapy at Columbia University Medical Center.
Dr. Subudhi is Assistant Professor, Genitourinary Medical Oncology, a medical oncologist and immunologist whose research focuses on the mechanisms and pathways within the immune system that are responsible for tumor rejection and clinical benefit. He earned a PhD in Biological Science from The University of Chicago Division of Biological Sciences, a MD at The University of Chicago Prizker School of Medicine, , and a BA in Biological Basis of Behavior from The University of Pennsylvania College of Arts and Sciences.
Dr. Wolchok is Chief of the Immuno-Oncology Service and holds The Lloyd J. Old Chair in Clinical Investigation at Memorial Sloan Kettering Cancer Center (MSK). He is also head of the Swim Across America – Ludwig Collaborative Laboratory; Associate Director of the Ludwig Center for Cancer Immunotherapy (LCCI); SU2C–ACS Lung Cancer Dream Team Co-leader and Director of the Parker Institute for Cancer Immunotherapy at MSK.
ApricityOncology Enables You To:
- Easily access the most relevant and timely research and clinical data based on your patient’s current clinical presentation.
- Proactively track the most relevant symptoms and biometric measures for your patient’s unique course of treatment.
- Respond to real-time information with timely intervention for potential adverse events.